Prihlásiť sa Zaregistrujte sa zadarmo

Beta spoločnosti Adma Biologics Inc

Aká je hodnota metriky Beta spoločnosti Adma Biologics Inc?

Hodnota metriky Beta spoločnosti Adma Biologics Inc je 1.41

Aká je definícia metriky Beta?



BETA koeficient vyjadruje či je akcia volatilnejšia ako celkový trh. Beta nižšie ako 1 značí, že akcia je menej volatilná ako trh a beta vyššie ako 1 značí, že akcia je volatilnejšia. Volatilita sa miera pomocou kolísavosti ceny akcie.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Adma Biologics Inc

Čomu sa venuje spoločnosť Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Firmy s metrikou beta podobnou spoločnosti Adma Biologics Inc